Three-year effectiveness of intravenous pamidronate versus pamidronate plus slow-release sodium fluoride for postmenopausal osteoporosis

Osteoporosis International

Volumn 14, Issue 6, 2003, Pages 500-506

  Morabito, N ^a,b   Gaudio, A ^b   Lasco, A ^b   Vergara, C ^b   Tallarida, F ^b   Crisafulli, G ^b   Trifiletti, A ^b   Cincotta, M ^b   Pizzoleo, M A ^b   Frisina, N ^b  

^a Palazzo Forte Gonzaga   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

BMD; Bone turnover; Fluoride; Osteoporosis; Pamidronate

Indexed keywords

FLUORIDE SODIUM; PAMIDRONIC ACID; PLACEBO; SOMATOMEDIN C;

ADULT; AMENORRHEA; ARTICLE; BONE DENSITY; BONE TURNOVER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SLOW RELEASE FORMULATION; SPINE RADIOGRAPHY;

ALKALINE PHOSPHATASE; BONE DENSITY; BONE RESORPTION; CALCIUM; DIPHOSPHONATES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYCHOLECALCIFEROLS; INFUSIONS, INTRAVENOUS; INSULIN-LIKE GROWTH FACTOR I; MIDDLE AGED; OSTEOCALCIN; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; PHOSPHORUS; PROSPECTIVE STUDIES; SODIUM FLUORIDE; TIME FACTORS; TREATMENT OUTCOME;

EID: 10744220742     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00198-003-1397-0     Document Type: Article

References (56)

1. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis: the Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333:1437-1443
2. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: Fracture Intervention Trial Research Group. Lancet 348:1535-1541
3. Orr-Walker B, Wattie DJ, Evans MC, Reid IR (1997) Effects of prolonged bisphosphonate therapy and its discontinuation on bone mineral density in post-menopausal osteoporosis. Clin Endocrinol (Oxf) 46:87-92
4. Devogelaer JP, Nagant de Deuxchaisnes C (1997) Use of pamidronate in chronic and acute bone loss conditions. Medicina (B Aires) 57:101-108
5. Parisi MS, Oliveri MB, Mautalen CA (2001) Bone mineral density response to long-term bisphosphonate therapy in fibrous dysplasia. J Clin Densitom 4:167-172
6. Heaney RP (1994) The bone-remodeling transient: implications for the interpretation of clinical studies of bone mass change. J Bone Miner Res 9:1515-1523
7. Stock JL, Bell NH, Chesnut CH 3rd, Ensrud KE, Genant HK, Harris ST, McClung MR, Singer FR, Yood RA, Pryor-Tillotson S, Wei L, Santora AC II (1997) Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. Am J Med 103:291-297
8. Goziotis A, Sukhu B, Torontali M, Dowhaniuk M, Tenenbaum HC (1995) Effects of bisphosphonates APD and HEBP on bone metabolism in vitro. Bone 16:317S-327S
9. Reinholz GG, Getz B, Pederson L, Sanders ES, Subramaniam M, Ingle JN, Spelsberg TC (2000) Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res 60:6001-6007
10. Erdtsieck RJ, Pols HA, Valk NK, van Ouwerkerk BM, Lamberts SW, Mulder P, Birkenhager JC (1995) Treatment of post-menopausal osteoporosis with a combination of growth hormone and pamidronate: a placebo controlled trial. Clin Endocrinol (Oxf) 43:557-565
11. Ringe JD, Rovati LC (2001) Treatment of osteoporosis in men with fluoride alone or in combination with bisphosphonates. Calcif Tissue Int 69:252-255
12. Farley JR, Wergedal JE, Baylink DJ (1983) Fluoride directly stimulates proliferation and alkaline phosphatase activity of bone-forming cells. Science 222:330-332
13. Reed BY, Zerwekh JE, Antich PP, Pak CY (1993) Fluoride-stimulated [3H]thymidine uptake in a human osteoblastic osteosarcoma cell line is dependent on transforming growth factor beta. J Bone Miner Res 8:19-25
14. Pak CY, Zerwekh JE, Antich P (1995) Anabolic effects of fluoride on bone. Trends Endocrinol Metab 6:229-234
15. Lau KH, Baylink DJ (1998) Molecular mechanism of action of fluoride on bone cells. J Bone Miner Res 13:1660-1667
16. Thiébaud D, Burckhardt P, Melchior J, Eckert P, Jacquet AF, Schnyder P, Gobelet C (1994) Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause. Osteoporos Int 4:76-83
17. Boutsen Y, Jamart J, Esselinckx W, Devogelaer JP (2001) Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. J Bone Miner Res 16:104-112
18. Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, Kantoff PW, Finkelstein JS (2001) Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 345:948-955
19. Krieg MA, Seydoux C, Sandini L, Goy JJ, Berguer DG, Thiebaud D, Burckhardt P (2001) Intravenous pamidronate as treatment for osteoporosis after heart transplantation: a prospective study. Osteoporos Int 12:112-116
20. Riggs BL, Hodgson SF, O'Fallon WM, Chao EY, Wahner HW, Muhs JM, Cedel SL, Melton LJ III (1990) Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 322:802-809
21. Mamelle N, Meunier PJ, Dusan R, Guillaume M, Martin JL, Gaucher A, Prost A, Zeigler G, Netter P (1988) Risk-benefit ratio of sodium fluoride in primary vertebral osteoporosis. Lancet 2:361-365
22. Pak CY, Sakhaee K, Adams-Huet B, Piziak V, Peterson RD, Poindexter JR (1995) Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Final report of a randomized controlled trial. Ann Intern Med 123:401-408
23. Pak CY, Adams-Huet B, Sakhaee K, Bell NH, Licata A, Johnston C, Rubin B, Bonnick S, Piziak V, Graham H, Ballard J, Berger R, Fears W, Breslau N, Rubin C (1996) Comparison of nonrandomized trials with slow-release sodium fluoride with a randomized placebo-controlled trial in postmenopausal osteoporosis. J Bone Miner Res 11:160-168
24. Farrerons J, Rodriguez de la Serna A, Guanabens N, Armadans L, Lopez-Navidad A, Yoldi B, Renau A, Vaque J (1997) Sodium fluoride treatment is a major protector against vertebral and nonvertebral fractures when compared with other common treatments of osteoporosis: a longitudinal, observational study. Calcif Tissue Int 60:250-254
25. Haguenauer D, Welch V, Shea B, Tugwell P, Adachi JD, Wells G (2000) Fluoride for the treatment of postmenopausal osteoporotic fractures: a meta-analysis. Osteoporos Int 11:727-738
26. Rubin CD, Pak CY, Adams-Huet B, Genant HK, Li J, Rao DS (2001) Sustained-release sodium fluoride in the treatment of the elderly with established osteoporosis. Arch Intern Med 161:2325-2333
27. Reginster JY, Rovati LC, Setnikar I (2001) Correct regimen of fluoride and calcium reduces the risk of vertebral fractures in postmenopausal osteoporosis. Osteoporos Int 12:800
28. Minne HW, Leidig G, Wuster C, Siromachkostov L, Baldauf G, Bickel R, Sauer P, Lojen M, Ziegler R (1988) A newly developed spine deformity index (SDI) to quantitate vertebral crush fractures in patients with osteoporosis. Bone Miner 3:335-349
29. World Health Organization Study Group (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 843
30. Valkema R,Vismans FJFE, Papapoulos SE, Pauwels EKJ, Bijvoet OLM (1989) Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD. Bone Miner 5:183-192
31. Reid IR, Wattie DJ, Evans MC, Gamble GD, Stapleton JP, Cornish J (1994) Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis. J Clin Endocrinol Metab 79:1595-1599
32. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ (1997) Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100:1475-1480
33. Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ (2000) Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27:687-694
34. Tonino RP, Meunier PJ, Emkey R, Rodriguez-Portales JA, Menkes CJ, Wasnich RD, Bone HG, Santora AC, Wu M, Desai R, Ross PD (2000) Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab 85:3109-3115
35. Chavassieux PM, Arlot ME, Roux JP, Portero N, Daifotis A, Yates AJ, Hamdy NA, Malice MP, Freedholm D, Meunier PJ (2000) Effects of alendronate on bone quality and remodeling in glucocorticoid-induced osteoporosis: a histomorphometric analysis of transiliac biopsies. J Bone Miner Res 15:754-762
36. Roschger P, Rinnerthaler S, Yates J, Rodan GA, Fratzl P, Klaushofer K (2001) Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 29:185-191
37. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH III, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and non-vertebral fractures in women with postmenopausal osteoporosis. JAMA 282:1344-1352
38. Bravenboer N, Papapoulos SE, Holzmann P, Hamdy NA, Netelenbos JC, Lips P (1999) Bone histomorphometric evaluation of pamidronate treatment in clinically manifest osteoporosis. Osteoporos Int 9:489-493
39. Chapurlat RD, Delmas PD, Liens D, Meunier PJ (1997) Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. J Bone Miner Res 12:1746-1752
40. Adamson BB, Gallacher SJ, Byars J, Ralston SH, Boyle IT, Boyce BF (1993) Mineralisation defects with pamidronate therapy for Paget's disease. Lancet 342:1459-1460
41. Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB (2000) Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15:613-620
42. Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB (2001) Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 28:524-531
43. Li J, Mashiba T, Burr DB (2001) Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage. Calcif Tissue Int 69:281-286
44. Kodama Y, Nakayama K, Fuse H, Fukumoto S, Kawahara H, Takahashi H, Kurokawa T, Sekiguchi C, Nakamura T, Matsumoto T (1997) Inhibition of bone resorption by pamidronate cannot restore normal gain in cortical bone mass and strength in tail-suspended rapidly growing rats. J Bone Miner Res 12:1058-1067
45. Bourrin S, Ammann P, Bonjour JP, Rizzoli R (2002) Recovery of proximal tibia bone mineral density and strength, but not cancellous bone architecture, after long-term bisphosphonate or selective estrogen receptor modulator therapy in aged rats. Bone 30:195-200
46. Zerwekh JE, Antich PP, Sakhaee K, Prior J, Gonzales J, Gottschalk F, Pak CY (1992) Lack of deleterious effect of slow-release sodium fluoride treatment on cortical bone histology and quality in osteoporotic patients. Bone Miner 18:65-76
47. Kragstrup J, Shijie Z, Mosekilde L, Melsen F (1989) Effects of sodium fluoride, vitamin D, and calcium on cortical bone remodeling in osteoporotic patients. Calcif Tissue Int 45:337-341
48. Riggs BL, Hodgson SF, O'Fallon WM, Chao EY, Wahner HW, Muhs JM, Cedel SL, Melton LJ III (1990 Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 322:802-809
49. Gutteridge DH, Boivin G, Meunier PJ (1990) Fluoride in postmenopausal osteoporosis: selective increase in external cortical porosity correlates with cancellous volume increase without change in cortical bone volume. In: Christiansen C, Overgaard K (eds) Osteoporosis 1990. Osteopress, Copenhagen, pp 718-720
50. Pak CY, Sakhaee K, Zerwekh JE, Parcel C, Peterson R, Johnson K (1989) Safe and effective treatment of osteoporosis with intermittent slow-release sodium fluoride: augmentation of vertebral bone mass and inhibition of fractures. J Clin Endocrinol Metab 68:150-159
51. Pak CY, Sakhaee K, Piziak V, Peterson RD, Breslau NA, Boyd P, Poindexter JR, Herzog J, Heard-Sakhaee A, Haynes S (1994) Slow-release sodium fluoride in the management of postmenopausal osteoporosis, a randomized controlled trial. Ann Intern Med 120:625-632
52. Pak CY, Sakhaee K, Parcel C, Poindexter J, Adams B, Bahar A, Beckley R (1990) Fluoride bioavailability from slow-release sodium fluoride given with calcium citrate. J Bone Miner Res 5:857-862
53. Rechler MM, Nissley SP (1990) Insulin-like growth factors. In: Sporn MB, Roberts AB (eds) Peptide growth factors and theirs receptors. Springer, Berlin Heidelberg New York, pp 263-346
54. Hock JM, Centrella M, Canalis E (1988) Insulin-like growth factor I has independent effects on bone matrix formation and cell replication. Endocrinology 122:254-260
55. Jones JI, Clemmons DR (1995) Insulin-like growth factors and their binding proteins: biological actions. Endocrin Rev 16:3-34
56. Turner CH, Garetto LP, Dunipace AJ, Zhang W, Wilson ME, Grynpas MD, Chachra D, McClintock R, Peacock M, Stookey GK (1997) Fluoride treatment increased serum IGF-1, bone turnover, and bone mass, but not bone strength, in rabbits. Calcif Tissue Int 61:77-83